Auspex Pharmaceuticals, Inc.

Quick facts

Phase 3 pipeline

• SD-809 · Neurology
  SD-809 is a selective vesicular monoamine transporter 2 (VMAT2) inhibitor that reduces the packaging and release of monoamines in presynaptic neurons.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Auspex Pharmaceuticals, Inc. portfolio CI brief
• Auspex Pharmaceuticals, Inc. pipeline updates RSS